Click here for slides on this topic


UKPDS

Abbreviation for the United Kingdom Prospective Diabetes Study. UKPDS was a landmark randomized, multi-center trial of glycaemic therapies among 5,102 patients with newly diagnosed type 2 diabetes. UKPDS ran for 20 years in 23 clinical sites in the United Kingdom. Data from UKPDS showed that complications of type 2 diabetes could be reduced by improving blood glucose and/or blood pressure control.
The following content matched the glossary term: UKPDS

Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy.

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of ADVANCE. Morton J, Zoungas S, Li Q, et al; on behalf of the ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy. Diabetes Care. 2012;35:2201-2206. Macro- and microvascular complications remain significant concerns in the treatment of patients with type 2 diabetes.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

Glycemic Control: How Low Should You Go?

Top

Glycemic Control: How Low Should You Go? NDEI Education Council Co-Chair Burton E. Sobel, MD, provides expert commentary on the debate over intensive versus somewhat less intensive glycemic control in the context of a recent study by Zhao et al assessing the impact of hypoglycemia associated with antihyperglycemic medications on vascular risk in type 2 diabetes

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

Trends in the risk for CHD among adults w/ diagnosed diabetes in the U.S.: findings from the national health & nutrition examination survey

Top

Ford ES. Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the u.s.: findings from the national health and nutrition examination survey, 1999-2008. Diabetes Care. 2011 Jun;34(6):1337-43. Epub 2011 Apr 19. Coronary heart disease (CHD) is a major cause of mortality among people with diabetes. The objective of this study was to examine the trend in an estimated 10-year risk for developing CHD among adults with diagnosed diabetes in the U.S.

Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from NHANES 1999-2008

Top

Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S. findings from the National Health and Nutrition Examination Survey, 1999 2008Ford ES. Diabetes Care. 2011 Apr 19. Epub ahead of print   Coronary heart disease (CHD) is a major cause of mortality among people with diabetes. The objective of this study was to examine the trend in an estimated 10-year risk for developing CHD among adults with diagnosed diabetes in the U.S.

10-year follow-up of intensive glucose control in type 2 diabetes

Top

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy.

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROactive 10.

Top

Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008;155(4):712-7. Epub 2008 Feb 21. Composite end points of major adverse cardiovascular events (MACEs) are standard measures for comparing treatment in large cardiovascular outcome studies.

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective

Top

Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism. 2006;55:S2-S5. The United Kingdom Prospective Diabetes Study shows sulfonylureas to be an effective first-line therapy for people with type 2 diabetes mellitus. The durability of the glycemic control obtained is dependent on the degree to which beta-cell function can be maintained, but sulfonylureas appear neither to increase nor to decrease the underlying rate of loss of beta-cell function.

Renal protection in diabetes: role of glycemic control

Top

Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol. 2006;17:S86-S89. Diabetes is the most common cause of ESRD in Western countries. This article describes the impact of glycemic control in the various stages of the disease and considers the impact of tight glycemic control on the development and progression of diabetic nephropathy (DN).

1 2 3 Next 

Slide Library Results

Search Results for: UKPDS Slides Found: 23
Sulfonylureas: Prescribing Considerations
Sulfonylureas: Prescribing Considerations
UKPDS Results of Intensive Therapy: Sulfonylurea and Insulin
UKPDS Results of Intensive Therapy: Metformin vs Conventional Therapy
UKPDS Results: Tight BP Control
Type 2 Diabetes: Pathogenesis in a Nutshell
UKPDS: Progressive Deterioration in Glycemic Control Over Time
UKPDS: Progressive Deterioration in beta-Cell Function Over Time
Compelling Indications for Hypertension Drug Classes
CVD Risk Reduction From Tight Control of BP and Glucose in Type 2 Diabetes
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Any Diabetes Endpoint
UKPDS: Intensive Metformin vs Conventional Therapy: Diabetes Endpoints
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive Metformin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Death From Any Cause
UKPDS: Intensive Metformin vs Conventional Therapy: Death From Any Cause
Meta-Analysis: Intensive vs Standard Glucose Treatment on A1C Concentration at Follow-Up
Meta-Analysis: Intensive vs Standard Glucose Treatment on Non-Fatal Myocardial Infarc
Meta-Analysis: Intensive vs Standard Glucose Treatment on CHD
Meta-Analysis: Conclusion
Trends in CHD Risk Among Adults With Diabetes: Design
Trends in CHD Risk Among Adults With Diabetes: Results
Glycemic Control Guidelines to Prevent Diabetic Foot Ulcers A1C PPT | NDEI